Wnt family ligands

Aβ42-IN-2 is a γ-secretase modulator extracted from patent WO2016070107, compound example 36. Aβ42-IN-2 has an IC 50 of 6.5 nM for Αβ 42 . Aβ42-IN-2 can be used for the research of Alzheimer's diseaseForm:SolidIC50&amp Target:Αβ 42

Aβ42-IN-2 is a γ-secretase modulator extracted from patent WO2016070107, compound example 36. Aβ42-IN-2 has an IC 50 of 6.5 nM for Αβ 42 . Aβ42-IN-2 can be used for the research of Alzheimer's diseaseIC50&amp Target:Αβ 42

Bilobetin, an active component of Ginkgo biloba , can reduce blood lipids and improve the effects of insulin . Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein

Bilobetin, an active component of Ginkgo biloba , can reduce blood lipids and improve the effects of insulin . Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein

Bilobetin, an active component of Ginkgo biloba , can reduce blood lipids and improve the effects of insulin . Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein

BMS-906024 is an orally active and selective γ-secretase (gamma secretase) inhibitor. BMS-906024 is a potent pan- Notch receptors inhibitor with IC 50 s of 1.6 nM, 0.7 nM, 3.4 nM, and 2.9 nM for Notch1, -2, -3, and -4 receptors, respectively.

BMS-983970 is an oral pan- Notch inhibitor for the treatment of multiplecancersIn VivoBMS-983970 demonstrates anti-tumor activity in T-cell acute lymphoblastic leukemia (T-ALL) and solid tumor xenograft models . MCE has not independently confirmed

BMS-983970 is an oral pan- Notch inhibitor for the treatment of multiplecancersIn VivoBMS-983970 demonstrates anti-tumor activity in T-cell acute lymphoblastic leukemia (T-ALL) and solid tumor xenograft models . MCE has not independently confirmed

BMS-983970 is an oral pan- Notch inhibitor for the treatment of multiplecancersIn VivoBMS-983970 demonstrates anti-tumor activity in T-cell acute lymphoblastic leukemia (T-ALL) and solid tumor xenograft models . MCE has not independently confirmed

BMS-983970 is an oral pan- Notch inhibitor for the treatment of multiplecancersIn VivoBMS-983970 demonstrates anti-tumor activity in T-cell acute lymphoblastic leukemia (T-ALL) and solid tumor xenograft models . MCE has not independently confirmed

BMS-983970 is an oral pan- Notch inhibitor for the treatment of multiplecancersIn VivoBMS-983970 demonstrates anti-tumor activity in T-cell acute lymphoblastic leukemia (T-ALL) and solid tumor xenograft models . MCE has not independently confirmed

BMS-983970 is an oral pan- Notch inhibitor for the treatment of multiplecancersIn VivoBMS-983970 demonstrates anti-tumor activity in T-cell acute lymphoblastic leukemia (T-ALL) and solid tumor xenograft models . MCE has not independently confirmed